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Methotrexate combined with omalizumab for difficult to treat urticaria: a further step-up 
treatment?
Dear Editor,
Classically, chronic urticaria has been treated following a stepwise approach where 
Omalizumab and other immunosuppressants occupy the last step. Omalizumab and Methotrexate 
have both been used separately for the treatment of urticaria1,2. We believe combination treatment 
with both agents is a valuable alternative for refractory chronic urticaria and other related diseases 
such as urticarial vasculitis. Here we report on two patients who responded to the combination 
treatment.
Patient 1 is a 53-year-old woman first assessed in January 2007 with a “hive”-like eruption 
resolving within twenty-four hours without hyperpigmentation. She also described raised red lines 
after minimal stroking of her skin. Clinical findings were consistent with chronic spontaneous 
urticaria and symptomatic dermographism. A combination of different H1 and H2 antihistamines, 
Montelukast and different forms of ultraviolet phototherapy were trialled with little clinical 
response. In June 2010, Azathioprine was started at a dose based on TPMT enzyme activity, but it 
was discontinued after one-month due to drug-induced neutropenia and hepatitis. In September 
2010, subcutaneous Methotrexate once weekly was introduced up to a dose of 25 mg once weekly, 
significantly reducing urticaria symptoms and the number of episodes. During that period, no 
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other side effects were observed and blood test monitoring remained stable. Although improved, 
her symptoms were still intolerable and she had to reduce her work hours as activity aggravated 
the dermographism. In February 2015, Omalizumab was added alongside the Methotrexate and 
titrated up to a total of 300mg four weekly and was associated with notable clinical improvement. 
In March 2016, a loss of efficacy of Omalizumab was reported by the patient after 3 weeks. Thus, 
the dose was increased to 300mg three weekly. She is currently taking Omalizumab combined 
with Methotrexate, and has been so for 5 years, with good control of her urticaria and without drug 
related adverse effects.
Patient 2 is a 58-year-old woman with a past history of chronic spontaneous urticaria and 
angioedema since February 2007. She was first assessed in the Photobiology Department in April 
2008 because of erythema over the dorsal arms following three to five minutes of sunlight 
exposure. On monochromator phototesting, an abnormal urticarial response within ultraviolet A 
and visible wavebands (335 to 400 nm) was found with minimal urticarial dose of 4700 mJcm-2 at 
365±30 nm [half-maximum bandwidth] waveband (reference range for delayed erythema ≥18000 
mJcm-2) nm and dose of 47000 mJcm-2 of 400±30 nm waveband (reference ≥56000 mJcm-2), 
without abnormal delayed responses. Solar simulator showed abnormal immediate urticarial 
response to UVA and visible light on the dorsal hand. These results were consistent with solar 
urticaria. Despite investigation no underlying cause was found so this was idiopathic solar 
urticaria. Over years her solar urticaria fluctuated in severity both clinically and as determined on 
phototesting. From 2008 to 2015, she took Omalizumab 300mg every four weeks and reported 
clinical improvement. However, it was discontinued due to constipation. Azathioprine was trialled 
but not tolerated due to nausea. Following this, a four-day course of high-dose intravenous 
immunoglobulin was given but it was stopped due to significant leukopaenia. Later, in 2015 she 
started subcutaneous Methotrexate 25mg per week with good tolerance and she continued it for 
one year. This provided the longest period of disease control. In November 2018, she developed 
wheals which resolved within a few days leaving bruising of the skin in her arms after sun 
exposure. Lesions were reproduceable on phototesting and histopathology showed a mixed 
inflammatory cell infiltrate with red cell extravasation consistent with leukocytoclastic vasculitis 
although there was no fibrinoid necrosis.  A diagnosis of urticarial vasculitis induced by sun 
exposure was made and she was initiated on Dapsone alongside Methotrexate. Unfortunately, she 
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immunosuppressant she had tolerated was Methotrexate, in December 2019 Omalizumab was 
reintroduced at 150mg once a month in combination with methotrexate 25mg once weekly. After 
3 months of treatment she reported a significant improvement of quality of life, with better control 
of the condition and without side effects. Monochromator phototesting to long UVA (365±27 nm 
waveband) performed on her forearm showed the same minimal urticarial dose (threshold 
response) as before starting the treatment, but there was a delay in the time to response compared 
with previous testing.
To our knowledge, this combination has not been previously reported for treatment of 
urticaria. We believe this is an effective treatment option when faced with refractory and severe 
chronic urticaria or urticarial vasculitis. 
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